New evidence published in The BMJ suggests obesity is rising fastest among younger adults in England, adding fresh urgency to the UK’s long-running debate over how to tackle diet-related disease. The analysis, based on electronic health records from more than 54 million adults between 2019 and 2025, also found that inequalities in obesity rates have widened since the covid-19 pandemic.
The findings come as ministers increasingly turn to weight-loss drugs such as GLP-1s as a tool to treat obesity. But the study authors warned that relying solely on lifelong drug therapies is unlikely to be sufficient, or sustainable, to address the wider obesity crisis.
Why the latest evidence matters for UK nutrition policy
According to the BMJ report, new obesity cases, defined as a body mass index of at least 30, rose from 26.3% of adults in November 2019 to 30.3% in April 2025. The results showed considerable variation by age, sex, socioeconomic status and ethnicity, with the largest increases seen among younger adults and people from disadvantaged groups. ([bmj.com](https://www.bmj.com/content/393/bmj-2026-100097?utm_source=openai))
That pattern has intensified pressure on policymakers to look beyond treatment alone and focus more on prevention. The researchers called for urgent action on the social and economic drivers of obesity and a stronger emphasis on populations at greatest risk. ([bmj.com](https://www.bmj.com/content/393/bmj-2026-100097?utm_source=openai))
Calls grow for broader action beyond weight-loss medicines
The BMJ coverage comes amid wider scrutiny of how governments respond to diet-related illness. In a separate BMJ article published on 15 July 2026, MPs said ministers must stand up to the food industry after decades of policy failure, arguing that tougher regulation on advertising, promotions and labelling is needed to make healthier choices easier. ([bmj.com](https://www.bmj.com/content/394/bmj-2026-100292?utm_source=openai))
That push for stronger food policy reflects a growing view that obesity is being shaped not just by individual behaviour, but by food environments, marketing and access to healthier options. The BMJ’s reporting also noted that the latest obesity trends are one reason the UK continues to face difficult questions about how much weight should be placed on medication versus prevention. ([bmj.com](https://www.bmj.com/content/393/bmj-2026-100097?utm_source=openai))
What it could mean for patients and the NHS
For patients, the findings underline that obesity remains a fast-moving public health challenge rather than a problem that can be solved by one intervention. For the NHS, they reinforce the need for a joined-up approach that combines clinical treatment with prevention efforts aimed at diet, food access and long-term lifestyle support. ([bmj.com](https://www.bmj.com/content/393/bmj-2026-100097?utm_source=openai))
The broader message from the new evidence is straightforward: weight-loss drugs may play an important role, but the UK’s nutrition and obesity strategy will need to do far more if it is to slow the rise in diet-related disease, especially among younger adults. ([bmj.com](https://www.bmj.com/content/393/bmj-2026-100097?utm_source=openai))
